Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy
Cerebrovascular dysfunction and cerebral amyloid angiopathy (CAA) are hallmark features of Alzheimer's disease (AD). Molecular damage to cerebrovessels in AD may result in alterations in vascular clearance mechanisms leading to amyloid deposition around blood vessels and diminished neurovascula...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2021.658605/full |
id |
doaj-413c822661384db6ab23f184dc5ed3cf |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Joseph O. Ojo Joseph O. Ojo Joseph O. Ojo Jon M. Reed Jon M. Reed Gogce Crynen Prashanthi Vallabhaneni James Evans Benjamin Shackleton Benjamin Shackleton Maximillian Eisenbaum Maximillian Eisenbaum Charis Ringland Charis Ringland Anastasia Edsell Michael Mullan Michael Mullan Fiona Crawford Fiona Crawford Fiona Crawford Corbin Bachmeier Corbin Bachmeier Corbin Bachmeier |
spellingShingle |
Joseph O. Ojo Joseph O. Ojo Joseph O. Ojo Jon M. Reed Jon M. Reed Gogce Crynen Prashanthi Vallabhaneni James Evans Benjamin Shackleton Benjamin Shackleton Maximillian Eisenbaum Maximillian Eisenbaum Charis Ringland Charis Ringland Anastasia Edsell Michael Mullan Michael Mullan Fiona Crawford Fiona Crawford Fiona Crawford Corbin Bachmeier Corbin Bachmeier Corbin Bachmeier Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy Frontiers in Aging Neuroscience cerebrovasculature Alzheimers disease cerebral amyloid angiopathy endothelial cells mural cells proteomics |
author_facet |
Joseph O. Ojo Joseph O. Ojo Joseph O. Ojo Jon M. Reed Jon M. Reed Gogce Crynen Prashanthi Vallabhaneni James Evans Benjamin Shackleton Benjamin Shackleton Maximillian Eisenbaum Maximillian Eisenbaum Charis Ringland Charis Ringland Anastasia Edsell Michael Mullan Michael Mullan Fiona Crawford Fiona Crawford Fiona Crawford Corbin Bachmeier Corbin Bachmeier Corbin Bachmeier |
author_sort |
Joseph O. Ojo |
title |
Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy |
title_short |
Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy |
title_full |
Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy |
title_fullStr |
Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy |
title_full_unstemmed |
Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy |
title_sort |
molecular pathobiology of the cerebrovasculature in aging and in alzheimers disease cases with cerebral amyloid angiopathy |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Aging Neuroscience |
issn |
1663-4365 |
publishDate |
2021-05-01 |
description |
Cerebrovascular dysfunction and cerebral amyloid angiopathy (CAA) are hallmark features of Alzheimer's disease (AD). Molecular damage to cerebrovessels in AD may result in alterations in vascular clearance mechanisms leading to amyloid deposition around blood vessels and diminished neurovascular-coupling. The sequelae of molecular events leading to these early pathogenic changes remains elusive. To address this, we conducted a comprehensive in-depth molecular characterization of the proteomic changes in enriched cerebrovessel fractions isolated from the inferior frontal gyrus of autopsy AD cases with low (85.5 ± 2.9 yrs) vs. high (81 ± 4.4 yrs) CAA score, aged-matched control (87.4 ± 1.5 yrs) and young healthy control (47 ± 3.3 yrs) cases. We employed a 10-plex tandem isobaric mass tag approach in combination with our ultra-high pressure liquid chromatography MS/MS (Q-Exactive) method. Enriched cerebrovascular fractions showed very high expression levels of proteins specific to endothelial cells, mural cells (pericytes and smooth muscle cells), and astrocytes. We observed 150 significantly regulated proteins in young vs. aged control cerebrovessels. The top pathways significantly modulated with aging included chemokine, reelin, HIF1α and synaptogenesis signaling pathways. There were 213 proteins significantly regulated in aged-matched control vs. high CAA cerebrovessels. The top three pathways significantly altered from this comparison were oxidative phosphorylation, Sirtuin signaling pathway and TCA cycle II. Comparison between low vs. high CAA cerebrovessels identified 84 significantly regulated proteins. Top three pathways significantly altered between low vs. high CAA cerebrovessels included TCA Cycle II, Oxidative phosphorylation and mitochondrial dysfunction. Notably, high CAA cases included more advanced AD pathology thus cerebrovascular effects may be driven by the severity of amyloid and Tangle pathology. These descriptive proteomic changes provide novel insights to explain the age-related and AD-related cerebrovascular changes contributing to AD pathogenesis. Particularly, disturbances in energy bioenergetics and mitochondrial biology rank among the top AD pathways altered in cerebrovessels. Targeting these failed mechanisms in endothelia and mural cells may provide novel disease modifying targets for developing therapeutic strategies against cerebrovascular deterioration and promoting cerebral perfusion in AD. Our future work will focus on interrogating and validating these novel targets and pathways and their functional significance. |
topic |
cerebrovasculature Alzheimers disease cerebral amyloid angiopathy endothelial cells mural cells proteomics |
url |
https://www.frontiersin.org/articles/10.3389/fnagi.2021.658605/full |
work_keys_str_mv |
AT josephoojo molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT josephoojo molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT josephoojo molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT jonmreed molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT jonmreed molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT gogcecrynen molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT prashanthivallabhaneni molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT jamesevans molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT benjaminshackleton molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT benjaminshackleton molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT maximillianeisenbaum molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT maximillianeisenbaum molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT charisringland molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT charisringland molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT anastasiaedsell molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT michaelmullan molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT michaelmullan molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT fionacrawford molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT fionacrawford molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT fionacrawford molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT corbinbachmeier molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT corbinbachmeier molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy AT corbinbachmeier molecularpathobiologyofthecerebrovasculatureinagingandinalzheimersdiseasecaseswithcerebralamyloidangiopathy |
_version_ |
1721438397091807232 |
spelling |
doaj-413c822661384db6ab23f184dc5ed3cf2021-05-17T12:49:20ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652021-05-011310.3389/fnagi.2021.658605658605Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid AngiopathyJoseph O. Ojo0Joseph O. Ojo1Joseph O. Ojo2Jon M. Reed3Jon M. Reed4Gogce Crynen5Prashanthi Vallabhaneni6James Evans7Benjamin Shackleton8Benjamin Shackleton9Maximillian Eisenbaum10Maximillian Eisenbaum11Charis Ringland12Charis Ringland13Anastasia Edsell14Michael Mullan15Michael Mullan16Fiona Crawford17Fiona Crawford18Fiona Crawford19Corbin Bachmeier20Corbin Bachmeier21Corbin Bachmeier22Roskamp Institute, Sarasota, FL, United StatesJames A. Haley Veterans' Hospital, Tampa, FL, United StatesThe Open University, Milton Keynes, United KingdomRoskamp Institute, Sarasota, FL, United StatesBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United StatesRoskamp Institute, Sarasota, FL, United StatesRoskamp Institute, Sarasota, FL, United StatesRoskamp Institute, Sarasota, FL, United StatesRoskamp Institute, Sarasota, FL, United StatesThe Open University, Milton Keynes, United KingdomRoskamp Institute, Sarasota, FL, United StatesThe Open University, Milton Keynes, United KingdomRoskamp Institute, Sarasota, FL, United StatesThe Open University, Milton Keynes, United KingdomRoskamp Institute, Sarasota, FL, United StatesRoskamp Institute, Sarasota, FL, United StatesThe Open University, Milton Keynes, United KingdomRoskamp Institute, Sarasota, FL, United StatesJames A. Haley Veterans' Hospital, Tampa, FL, United StatesThe Open University, Milton Keynes, United KingdomRoskamp Institute, Sarasota, FL, United StatesThe Open University, Milton Keynes, United KingdomBay Pines VA Healthcare System, Bay Pines, FL, United StatesCerebrovascular dysfunction and cerebral amyloid angiopathy (CAA) are hallmark features of Alzheimer's disease (AD). Molecular damage to cerebrovessels in AD may result in alterations in vascular clearance mechanisms leading to amyloid deposition around blood vessels and diminished neurovascular-coupling. The sequelae of molecular events leading to these early pathogenic changes remains elusive. To address this, we conducted a comprehensive in-depth molecular characterization of the proteomic changes in enriched cerebrovessel fractions isolated from the inferior frontal gyrus of autopsy AD cases with low (85.5 ± 2.9 yrs) vs. high (81 ± 4.4 yrs) CAA score, aged-matched control (87.4 ± 1.5 yrs) and young healthy control (47 ± 3.3 yrs) cases. We employed a 10-plex tandem isobaric mass tag approach in combination with our ultra-high pressure liquid chromatography MS/MS (Q-Exactive) method. Enriched cerebrovascular fractions showed very high expression levels of proteins specific to endothelial cells, mural cells (pericytes and smooth muscle cells), and astrocytes. We observed 150 significantly regulated proteins in young vs. aged control cerebrovessels. The top pathways significantly modulated with aging included chemokine, reelin, HIF1α and synaptogenesis signaling pathways. There were 213 proteins significantly regulated in aged-matched control vs. high CAA cerebrovessels. The top three pathways significantly altered from this comparison were oxidative phosphorylation, Sirtuin signaling pathway and TCA cycle II. Comparison between low vs. high CAA cerebrovessels identified 84 significantly regulated proteins. Top three pathways significantly altered between low vs. high CAA cerebrovessels included TCA Cycle II, Oxidative phosphorylation and mitochondrial dysfunction. Notably, high CAA cases included more advanced AD pathology thus cerebrovascular effects may be driven by the severity of amyloid and Tangle pathology. These descriptive proteomic changes provide novel insights to explain the age-related and AD-related cerebrovascular changes contributing to AD pathogenesis. Particularly, disturbances in energy bioenergetics and mitochondrial biology rank among the top AD pathways altered in cerebrovessels. Targeting these failed mechanisms in endothelia and mural cells may provide novel disease modifying targets for developing therapeutic strategies against cerebrovascular deterioration and promoting cerebral perfusion in AD. Our future work will focus on interrogating and validating these novel targets and pathways and their functional significance.https://www.frontiersin.org/articles/10.3389/fnagi.2021.658605/fullcerebrovasculatureAlzheimers diseasecerebral amyloid angiopathyendothelial cellsmural cellsproteomics |